Under the terms of the agreement, Foamix will receive certain development fees and milestone payments. Upon commercialization of the product, Foamix will receive royalty based on net sales.
The use of foam provides controlled delivery of a variety of active ingredients. They are also able to enhance intradermal delivery of actives, for optimal effect. Psoriasis is a skin condition that commonly causes red scaly patches to appear on the skin.
“We are proud to partner with Dr Reddy's who is building a specialty pharmaceutical presence in branded dermatology by developing innovative topical products, both internally and through third party in-licensing, that will be detailed directly to dermatologists,” said Foamix CEO, Dr Dov Tamarkin.